SlideShare a Scribd company logo
Biochempeg https://www.biochempeg.com
ADC Drugs to be Launched In 2020
On February 10, 2020, Clarivate Analytics released the "The 2020 Cortellis
Drugs to Watch" annual report, predicting 11 new drugs that will be launched
in 2020 and with sales expected to exceed $ 1 billion in 2024. Among these 11
drugs, 2 are anti-tumor drugs. Coincidentally, these 2 drugs are
Antibody–Drug Conjugates (ADC).
Antibody–Drug Conjugates (hereinafter referred to as ADC) are made up of
monoclonal antibodies that target specific antigens through a linker and highly
efficient cytotoxic small molecules. From the design point of view, ADC can
use the specificity of antibodies and antigens to focus cytotoxic small
molecules on target cells "precisely" and then kill them. Due to the extremely
military positioning and tracking missiles, the industry has always referred to it
as a "biological missile."
Origin: https://www.adcreview.com
Biochempeg https://www.biochempeg.com
However, due to the particularity of the design concept and its structure,
the technical barriers of ADC are higher than that of general biological drugs.
Because of this, despite several decades of development, there are currently
only 7 ADC products approved worldwide. Compared with the hundreds of
thousands of chemical and other biological drugs approved in recent years,
ADC appears to be too few.
The two protagonists introduced today-Enhertu and Sacituzumab govitecan
are the latest representatives of ADC.
1. Enhertu: Rising stars against Her2-positive solid
tumors
Enhertu's original research company is Daiichi Sankyo, which is an ADC
composed of trastuzumab and ixiticon derivatives. In April 2019, AstraZeneca
and Daiichi Sankyo signed a cooperation agreement of up to 6.9 billion US
dollars for Enhertu, which made it famous. In December of the same year, the
Phase II clinical data published by the New England Journal of Medicine really
made Enhertu a hit again.
According to the published data, among 184 patients with unresectable or
metastatic Her2-positive breast cancer who have used two or more
Her2-positive treatment regimens but the disease is still progressing, Enhertu
is used as follows:
1. The objective response rate (ORR) is 60.9%, and the disease control rate is
97.3%.
Biochempeg https://www.biochempeg.com
2. The duration of response (DOR) reaches 14.8 months.
3. The progression-free survival (PFS) reaches 16.4 months.
Biochempeg https://www.biochempeg.com
In cases where Her2-positive breast cancer patients have exhausted almost all
Her2-targeted drugs and still cannot control disease progression, Enhertu is
still able to relieve nearly 61% of patients, and its clinical value is self-evident.
Based on the above data, Enhertu received accelerated approval from the
FDA in December 2019. In addition to "accelerated approval", Enhertu also
obtained the "fast track designation, accelerated approval, and priority review"
qualification.
For other solid tumors, Enhertu has also shown positive results in gastric
cancer. In January 2020, AstraZeneca announced that the drug has reached
the clinical endpoint in Phase II clinical trials on Her2-positive gastric cancer.
In addition to breast cancer and gastric cancer, the drug is used in colorectal
cancer, NSCLC, and clinical trials of combined PD1 inhibitors in an orderly
manner.
Based on multiple positive clinical data, Clarivate predicts that the drug's
global market will exceed US $ 2.6 billion in 2024.
Origin: Clarivate Analytics Cortellis Competitive Intelligence
Biochempeg https://www.biochempeg.com
2. Sacituzumab govitecan: new hope for triple negative
breast cancer
The original company of Sacituzumab govitecan is Immunomedics, which is
formed by coupling the monoclonal antibody hRS7 targeting TROP-2 protein
with the active metabolite of irinotecan and is currently in the pre-registration
stage. Once the drug is approved, it will be the first-in-class in the TROP-2 field.
In February 2019, a piece of data from the New England Journal of Medicine
showed that among 108 patients with metastatic triple-negative breast cancer
who had received at least 2 treatment options, Sacituzumab govitecan was
treated as a single agent:
1. The overall remission rate is 33.3%, and the clinical benefit rate is 45.4%.
2. The duration of response (DOR) reaches 7.7 months.
Biochempeg https://www.biochempeg.com
3. The median progression-free survival (PFS) was 5.5 months, and the
estimated overall survival (OS) was 13 months.
Although the clinical data is strong, unfortunately, due to CMC issues, the FDA
rejected the drug's marketing application in January 2019. However, in
December of the same year, Immunomedics resubmitted its marketing
application to the FDA. The current tentative PDUFA date is June 2020.
From the point of view of action mechanism, TROP-2 is abundantly expressed
in various tumor cells (such as breast cancer, cervical cancer, colorectal
cancer, renal cancer, liver cancer, lung cancer, pancreatic cancer, prostate
cancer, etc.). In theory, the drug has therapeutic potential for various solid
tumors.
In my opinion, the approval of Sacituzumab govitecan is only a matter of time,
and the drug has great potential in many solid tumors. As Clarivate predicted,
the drug will become a blockbuster in 2024, and global sales are expected to
be US $ 1.27 billion.
Biochempeg https://www.biochempeg.com
Origin: Clarivate Analytics Cortellis Competitive Intelligence
Conclusion
From the moment the design concept of the ADC drug was proposed,
scientists hoped that the ADC could partially solve the limitations of the poor
efficacy of naked antibodies, and at the same time make up for the
shortcomings of cytotoxic small molecules that are too toxic to be prepared.
Reflecting this hope in the clinic, it can be found that the ADC drugs
represented by Enhertu and Sacituzumab govitecan are indeed very superior
in tumors, especially malignant tumors.
1. Enhertu is the second ADC approved for Her2-positive breast cancer after
Roche Kadcyla. It not only performs strongly in advanced Her2-positive breast
cancer, but also has the most potential for breakthroughs in solid tumors such
as gastric cancer and NSCLC .
2. Sacituzumab govitecan became the first-in-class in the TROP-2 field is
almost a matter of course. Its listing not only provides new hope for the
treatment of triple negative breast cancer, but also confirms the potential of the
new target TROP-2 in tumors.

More Related Content

What's hot

Global gene therapy market & pipeline insight
Global gene therapy market & pipeline insightGlobal gene therapy market & pipeline insight
Global gene therapy market & pipeline insight
KuicK Research
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
DoriaFang
 
Global Transactions in Pharma/Biotech
Global Transactions in Pharma/BiotechGlobal Transactions in Pharma/Biotech
Global Transactions in Pharma/Biotech
Pharma Intelligence
 
Pharma R&D Annual Review 2016 Webinar
Pharma R&D Annual Review 2016 WebinarPharma R&D Annual Review 2016 Webinar
Pharma R&D Annual Review 2016 Webinar
Pharma Intelligence
 
Global cancer cdk inhibitors market & clinical pipeline outlook 2022
Global cancer cdk inhibitors market & clinical pipeline outlook 2022Global cancer cdk inhibitors market & clinical pipeline outlook 2022
Global cancer cdk inhibitors market & clinical pipeline outlook 2022
KuicK Research
 
Global cancer kinase inhibitors market
Global cancer kinase inhibitors marketGlobal cancer kinase inhibitors market
Global cancer kinase inhibitors market
KuicK Research
 
Global hiv vaccine market future outlook
Global hiv vaccine market future outlookGlobal hiv vaccine market future outlook
Global hiv vaccine market future outlook
KuicK Research
 
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentPeptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
DoriaFang
 
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...
KuicK Research
 
Global interferon market & pipeline analysis 2015
Global interferon market & pipeline analysis 2015Global interferon market & pipeline analysis 2015
Global interferon market & pipeline analysis 2015
KuicK Research
 
Global insulin patch market opportunity analysis
Global insulin patch market opportunity analysisGlobal insulin patch market opportunity analysis
Global insulin patch market opportunity analysis
KuicK Research
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Pharma Intelligence
 
Celltrion Healthcare Pipeline
Celltrion Healthcare PipelineCelltrion Healthcare Pipeline
Celltrion Healthcare Pipeline
celltrionh
 
Global lung cancer vaccine market & pipeline outlook 2022
Global lung cancer vaccine market & pipeline outlook 2022Global lung cancer vaccine market & pipeline outlook 2022
Global lung cancer vaccine market & pipeline outlook 2022
Rajesh Sarma
 
Global peptide vaccine market & clinical pipeline outlook 2020
Global peptide vaccine market & clinical pipeline outlook 2020Global peptide vaccine market & clinical pipeline outlook 2020
Global peptide vaccine market & clinical pipeline outlook 2020
KuicK Research
 
Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)
celltrionh
 
Top 5 promising stem cell stocks
 Top 5 promising stem cell stocks Top 5 promising stem cell stocks
Top 5 promising stem cell stocks
Avi Surana
 

What's hot (17)

Global gene therapy market & pipeline insight
Global gene therapy market & pipeline insightGlobal gene therapy market & pipeline insight
Global gene therapy market & pipeline insight
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
 
Global Transactions in Pharma/Biotech
Global Transactions in Pharma/BiotechGlobal Transactions in Pharma/Biotech
Global Transactions in Pharma/Biotech
 
Pharma R&D Annual Review 2016 Webinar
Pharma R&D Annual Review 2016 WebinarPharma R&D Annual Review 2016 Webinar
Pharma R&D Annual Review 2016 Webinar
 
Global cancer cdk inhibitors market & clinical pipeline outlook 2022
Global cancer cdk inhibitors market & clinical pipeline outlook 2022Global cancer cdk inhibitors market & clinical pipeline outlook 2022
Global cancer cdk inhibitors market & clinical pipeline outlook 2022
 
Global cancer kinase inhibitors market
Global cancer kinase inhibitors marketGlobal cancer kinase inhibitors market
Global cancer kinase inhibitors market
 
Global hiv vaccine market future outlook
Global hiv vaccine market future outlookGlobal hiv vaccine market future outlook
Global hiv vaccine market future outlook
 
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentPeptide drug conjugates (pd cs) new generation of targeted cancer treatment
Peptide drug conjugates (pd cs) new generation of targeted cancer treatment
 
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...
 
Global interferon market & pipeline analysis 2015
Global interferon market & pipeline analysis 2015Global interferon market & pipeline analysis 2015
Global interferon market & pipeline analysis 2015
 
Global insulin patch market opportunity analysis
Global insulin patch market opportunity analysisGlobal insulin patch market opportunity analysis
Global insulin patch market opportunity analysis
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
 
Celltrion Healthcare Pipeline
Celltrion Healthcare PipelineCelltrion Healthcare Pipeline
Celltrion Healthcare Pipeline
 
Global lung cancer vaccine market & pipeline outlook 2022
Global lung cancer vaccine market & pipeline outlook 2022Global lung cancer vaccine market & pipeline outlook 2022
Global lung cancer vaccine market & pipeline outlook 2022
 
Global peptide vaccine market & clinical pipeline outlook 2020
Global peptide vaccine market & clinical pipeline outlook 2020Global peptide vaccine market & clinical pipeline outlook 2020
Global peptide vaccine market & clinical pipeline outlook 2020
 
Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)
 
Top 5 promising stem cell stocks
 Top 5 promising stem cell stocks Top 5 promising stem cell stocks
Top 5 promising stem cell stocks
 

Similar to Adc drugs to be launched in 2020

New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
DoriaFang
 
Summary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdfSummary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdf
Huateng Pharma
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3
ScottJordan
 
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
Bret Jensen
 
Download Global antibody drug conjugate market & pipeline insight2020
Download Global antibody drug conjugate market & pipeline insight2020Download Global antibody drug conjugate market & pipeline insight2020
Download Global antibody drug conjugate market & pipeline insight2020
KuicK Research
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
DoriaFang
 
Homework
HomeworkHomework
Homework
harshi2911
 
Global breast cancer monoclonal antibodies market outlook 2020 1
Global breast cancer monoclonal antibodies market outlook 2020 1Global breast cancer monoclonal antibodies market outlook 2020 1
Global breast cancer monoclonal antibodies market outlook 2020 1
KuicK Research
 
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Michael Sheckler
 
Us cancer vaccine market outlook 2020
Us cancer vaccine market outlook 2020Us cancer vaccine market outlook 2020
Us cancer vaccine market outlook 2020
KuicK Research
 
From biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to successFrom biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to success
National Institute of Biologics
 
Nature medicine top ten advancements in biomedicine in 2020
Nature medicine top ten advancements in biomedicine in 2020Nature medicine top ten advancements in biomedicine in 2020
Nature medicine top ten advancements in biomedicine in 2020
DoriaFang
 
Slide Presentation on Biosceptre International Ltd.
Slide Presentation on Biosceptre International Ltd.Slide Presentation on Biosceptre International Ltd.
Slide Presentation on Biosceptre International Ltd.
Crystal Research Associates
 
Directed Project
Directed ProjectDirected Project
Directed Project
Krishna Yanamandra
 
Global breast cancer monoclonal antibodies market outlook 2020
Global breast cancer monoclonal antibodies market outlook 2020Global breast cancer monoclonal antibodies market outlook 2020
Global breast cancer monoclonal antibodies market outlook 2020
KuicK Research
 
Download Global breast cancer monoclonal antibodies market outlook 2020
Download Global breast cancer monoclonal antibodies market outlook 2020Download Global breast cancer monoclonal antibodies market outlook 2020
Download Global breast cancer monoclonal antibodies market outlook 2020
KuicK Research
 
Download Global breast cancer vaccine market & clinical pipeline outlook ...
Download Global breast cancer vaccine market & clinical pipeline outlook ...Download Global breast cancer vaccine market & clinical pipeline outlook ...
Download Global breast cancer vaccine market & clinical pipeline outlook ...
KuicK Research
 
Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015
KuicK Research
 
What are the world's top selling drugs
What are the world's top selling drugsWhat are the world's top selling drugs
What are the world's top selling drugs
DoriaFang
 
translational biotechnology-Amgen -Geeta Iyer -4-48-16
translational biotechnology-Amgen -Geeta Iyer -4-48-16translational biotechnology-Amgen -Geeta Iyer -4-48-16
translational biotechnology-Amgen -Geeta Iyer -4-48-16
Geeta Iyer
 

Similar to Adc drugs to be launched in 2020 (20)

New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdfSummary of ADCs in Clinical Phase 3.pdf
Summary of ADCs in Clinical Phase 3.pdf
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3
 
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
 
Download Global antibody drug conjugate market & pipeline insight2020
Download Global antibody drug conjugate market & pipeline insight2020Download Global antibody drug conjugate market & pipeline insight2020
Download Global antibody drug conjugate market & pipeline insight2020
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
Homework
HomeworkHomework
Homework
 
Global breast cancer monoclonal antibodies market outlook 2020 1
Global breast cancer monoclonal antibodies market outlook 2020 1Global breast cancer monoclonal antibodies market outlook 2020 1
Global breast cancer monoclonal antibodies market outlook 2020 1
 
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
 
Us cancer vaccine market outlook 2020
Us cancer vaccine market outlook 2020Us cancer vaccine market outlook 2020
Us cancer vaccine market outlook 2020
 
From biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to successFrom biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to success
 
Nature medicine top ten advancements in biomedicine in 2020
Nature medicine top ten advancements in biomedicine in 2020Nature medicine top ten advancements in biomedicine in 2020
Nature medicine top ten advancements in biomedicine in 2020
 
Slide Presentation on Biosceptre International Ltd.
Slide Presentation on Biosceptre International Ltd.Slide Presentation on Biosceptre International Ltd.
Slide Presentation on Biosceptre International Ltd.
 
Directed Project
Directed ProjectDirected Project
Directed Project
 
Global breast cancer monoclonal antibodies market outlook 2020
Global breast cancer monoclonal antibodies market outlook 2020Global breast cancer monoclonal antibodies market outlook 2020
Global breast cancer monoclonal antibodies market outlook 2020
 
Download Global breast cancer monoclonal antibodies market outlook 2020
Download Global breast cancer monoclonal antibodies market outlook 2020Download Global breast cancer monoclonal antibodies market outlook 2020
Download Global breast cancer monoclonal antibodies market outlook 2020
 
Download Global breast cancer vaccine market & clinical pipeline outlook ...
Download Global breast cancer vaccine market & clinical pipeline outlook ...Download Global breast cancer vaccine market & clinical pipeline outlook ...
Download Global breast cancer vaccine market & clinical pipeline outlook ...
 
Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015
 
What are the world's top selling drugs
What are the world's top selling drugsWhat are the world's top selling drugs
What are the world's top selling drugs
 
translational biotechnology-Amgen -Geeta Iyer -4-48-16
translational biotechnology-Amgen -Geeta Iyer -4-48-16translational biotechnology-Amgen -Geeta Iyer -4-48-16
translational biotechnology-Amgen -Geeta Iyer -4-48-16
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
DoriaFang
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
DoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
DoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
DoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
DoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
DoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
DoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
DoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
DoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
DoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
DoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
DoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
DoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
DoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
DoriaFang
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
DoriaFang
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
DoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
 

Recently uploaded

Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian MatkaDpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
IPLTech Electric
 
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Stone Art Hub
 
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Kalyan Satta Matka Guessing Matka Result Main Bazar chart
 
State of D2C in India: A Logistics Update
State of D2C in India: A Logistics UpdateState of D2C in India: A Logistics Update
State of D2C in India: A Logistics Update
RedSeer
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
dazzjoker
 
list of states and organizations .pdf
list of  states  and  organizations .pdflist of  states  and  organizations .pdf
list of states and organizations .pdf
Rbc Rbcua
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
my Pandit
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
obriengroupinc04
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
Harwinder Singh
 
GKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt PresentationGKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt Presentation
GraceKohler1
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
CIOWomenMagazine
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
IMG_20240615_091110.pdf dpboss guessing
IMG_20240615_091110.pdf dpboss  guessingIMG_20240615_091110.pdf dpboss  guessing
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
BBPMedia1
 
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
Ksquare Energy Pvt. Ltd.
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
concepsionchomo153
 
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
Cambridge Product Management Network
 

Recently uploaded (20)

Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian MatkaDpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
 
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
 
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
 
State of D2C in India: A Logistics Update
State of D2C in India: A Logistics UpdateState of D2C in India: A Logistics Update
State of D2C in India: A Logistics Update
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
 
list of states and organizations .pdf
list of  states  and  organizations .pdflist of  states  and  organizations .pdf
list of states and organizations .pdf
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
 
GKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt PresentationGKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt Presentation
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
IMG_20240615_091110.pdf dpboss guessing
IMG_20240615_091110.pdf dpboss  guessingIMG_20240615_091110.pdf dpboss  guessing
IMG_20240615_091110.pdf dpboss guessing
 
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
 
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
 
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
 

Adc drugs to be launched in 2020

  • 1. Biochempeg https://www.biochempeg.com ADC Drugs to be Launched In 2020 On February 10, 2020, Clarivate Analytics released the "The 2020 Cortellis Drugs to Watch" annual report, predicting 11 new drugs that will be launched in 2020 and with sales expected to exceed $ 1 billion in 2024. Among these 11 drugs, 2 are anti-tumor drugs. Coincidentally, these 2 drugs are Antibody–Drug Conjugates (ADC). Antibody–Drug Conjugates (hereinafter referred to as ADC) are made up of monoclonal antibodies that target specific antigens through a linker and highly efficient cytotoxic small molecules. From the design point of view, ADC can use the specificity of antibodies and antigens to focus cytotoxic small molecules on target cells "precisely" and then kill them. Due to the extremely military positioning and tracking missiles, the industry has always referred to it as a "biological missile." Origin: https://www.adcreview.com
  • 2. Biochempeg https://www.biochempeg.com However, due to the particularity of the design concept and its structure, the technical barriers of ADC are higher than that of general biological drugs. Because of this, despite several decades of development, there are currently only 7 ADC products approved worldwide. Compared with the hundreds of thousands of chemical and other biological drugs approved in recent years, ADC appears to be too few. The two protagonists introduced today-Enhertu and Sacituzumab govitecan are the latest representatives of ADC. 1. Enhertu: Rising stars against Her2-positive solid tumors Enhertu's original research company is Daiichi Sankyo, which is an ADC composed of trastuzumab and ixiticon derivatives. In April 2019, AstraZeneca and Daiichi Sankyo signed a cooperation agreement of up to 6.9 billion US dollars for Enhertu, which made it famous. In December of the same year, the Phase II clinical data published by the New England Journal of Medicine really made Enhertu a hit again. According to the published data, among 184 patients with unresectable or metastatic Her2-positive breast cancer who have used two or more Her2-positive treatment regimens but the disease is still progressing, Enhertu is used as follows: 1. The objective response rate (ORR) is 60.9%, and the disease control rate is 97.3%.
  • 3. Biochempeg https://www.biochempeg.com 2. The duration of response (DOR) reaches 14.8 months. 3. The progression-free survival (PFS) reaches 16.4 months.
  • 4. Biochempeg https://www.biochempeg.com In cases where Her2-positive breast cancer patients have exhausted almost all Her2-targeted drugs and still cannot control disease progression, Enhertu is still able to relieve nearly 61% of patients, and its clinical value is self-evident. Based on the above data, Enhertu received accelerated approval from the FDA in December 2019. In addition to "accelerated approval", Enhertu also obtained the "fast track designation, accelerated approval, and priority review" qualification. For other solid tumors, Enhertu has also shown positive results in gastric cancer. In January 2020, AstraZeneca announced that the drug has reached the clinical endpoint in Phase II clinical trials on Her2-positive gastric cancer. In addition to breast cancer and gastric cancer, the drug is used in colorectal cancer, NSCLC, and clinical trials of combined PD1 inhibitors in an orderly manner. Based on multiple positive clinical data, Clarivate predicts that the drug's global market will exceed US $ 2.6 billion in 2024. Origin: Clarivate Analytics Cortellis Competitive Intelligence
  • 5. Biochempeg https://www.biochempeg.com 2. Sacituzumab govitecan: new hope for triple negative breast cancer The original company of Sacituzumab govitecan is Immunomedics, which is formed by coupling the monoclonal antibody hRS7 targeting TROP-2 protein with the active metabolite of irinotecan and is currently in the pre-registration stage. Once the drug is approved, it will be the first-in-class in the TROP-2 field. In February 2019, a piece of data from the New England Journal of Medicine showed that among 108 patients with metastatic triple-negative breast cancer who had received at least 2 treatment options, Sacituzumab govitecan was treated as a single agent: 1. The overall remission rate is 33.3%, and the clinical benefit rate is 45.4%. 2. The duration of response (DOR) reaches 7.7 months.
  • 6. Biochempeg https://www.biochempeg.com 3. The median progression-free survival (PFS) was 5.5 months, and the estimated overall survival (OS) was 13 months. Although the clinical data is strong, unfortunately, due to CMC issues, the FDA rejected the drug's marketing application in January 2019. However, in December of the same year, Immunomedics resubmitted its marketing application to the FDA. The current tentative PDUFA date is June 2020. From the point of view of action mechanism, TROP-2 is abundantly expressed in various tumor cells (such as breast cancer, cervical cancer, colorectal cancer, renal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, etc.). In theory, the drug has therapeutic potential for various solid tumors. In my opinion, the approval of Sacituzumab govitecan is only a matter of time, and the drug has great potential in many solid tumors. As Clarivate predicted, the drug will become a blockbuster in 2024, and global sales are expected to be US $ 1.27 billion.
  • 7. Biochempeg https://www.biochempeg.com Origin: Clarivate Analytics Cortellis Competitive Intelligence Conclusion From the moment the design concept of the ADC drug was proposed, scientists hoped that the ADC could partially solve the limitations of the poor efficacy of naked antibodies, and at the same time make up for the shortcomings of cytotoxic small molecules that are too toxic to be prepared. Reflecting this hope in the clinic, it can be found that the ADC drugs represented by Enhertu and Sacituzumab govitecan are indeed very superior in tumors, especially malignant tumors. 1. Enhertu is the second ADC approved for Her2-positive breast cancer after Roche Kadcyla. It not only performs strongly in advanced Her2-positive breast cancer, but also has the most potential for breakthroughs in solid tumors such as gastric cancer and NSCLC . 2. Sacituzumab govitecan became the first-in-class in the TROP-2 field is almost a matter of course. Its listing not only provides new hope for the treatment of triple negative breast cancer, but also confirms the potential of the new target TROP-2 in tumors.